tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Crinetics Pharma Stocks Surge Amid New Study Launch

Crinetics Pharma Stocks Surge Amid New Study Launch

Crinetics Pharmaceuticals ( (CRNX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.

TipRanks Cyber Monday Sale

Crinetics Pharmaceuticals has seen its stock price rise following the initiation of a Phase 1/2 study for its candidate CRN09682, aimed at targeting specific tumors. Additionally, the company’s price target has been raised due to strategic initiatives and promising growth prospects, including a successful earnings call that highlighted their PALSONIFY product. This reflects increased confidence in their market entry and financial position.

More about Crinetics Pharmaceuticals

YTD Price Performance: -12.22%

Average Trading Volume: 1,642,879

Technical Sentiment Signal: Strong Buy

Current Market Cap: $4.29B

For further insights into CRNX stock on TipRanks’ Stock Analysis page.

See more of today’s top stock gainers and losers.

Disclaimer & DisclosureReport an Issue

1